[HTML][HTML] Lung screening benefits and challenges: a review of the data and outline for implementation
J Sands, MC Tammemägi, S Couraud… - Journal of Thoracic …, 2021 - Elsevier
Lung cancer is the leading cause of cancer-related deaths worldwide, accounting for almost
a fifth of all cancer-related deaths. Annual computed tomographic lung cancer screening …
a fifth of all cancer-related deaths. Annual computed tomographic lung cancer screening …
Small cell lung cancer, version 2.2022, NCCN clinical practice guidelines in oncology
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung
Cancer (SCLC) provide recommended management for patients with SCLC, including …
Cancer (SCLC) provide recommended management for patients with SCLC, including …
Tarlatamab for patients with previously treated small-cell lung cancer
MJ Ahn, BC Cho, E Felip, I Korantzis… - … England Journal of …, 2023 - Mass Medical Soc
Background Tarlatamab, a bispecific T-cell engager immunotherapy targeting delta-like
ligand 3 and CD3, showed promising antitumor activity in a phase 1 trial in patients with …
ligand 3 and CD3, showed promising antitumor activity in a phase 1 trial in patients with …
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
J Trigo, V Subbiah, B Besse, V Moreno, R López… - The lancet …, 2020 - thelancet.com
Background Few options exist for treatment of patients with small-cell lung cancer (SCLC)
after failure of first-line therapy. Lurbinectedin is a selective inhibitor of oncogenic …
after failure of first-line therapy. Lurbinectedin is a selective inhibitor of oncogenic …
NCCN guidelines insights: small cell lung cancer, version 2.2018
The NCCN Guidelines for Small Cell Lung Cancer (SCLC) address all aspects of disease
management. These NCCN Guidelines Insights focus on recent updates to the NCCN …
management. These NCCN Guidelines Insights focus on recent updates to the NCCN …
Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses
I Cañadas, R Thummalapalli, JW Kim, S Kitajima… - Nature medicine, 2018 - nature.com
Mesenchymal tumor subpopulations secrete pro-tumorigenic cytokines and promote
treatment resistance,,–. This phenomenon has been implicated in chemorefractory small cell …
treatment resistance,,–. This phenomenon has been implicated in chemorefractory small cell …
NCCN guidelines® insights: lung cancer screening, version 1.2022: featured updates to the NCCN guidelines
The NCCN Guidelines for Lung Cancer Screening recommend criteria for selecting
individuals for screening and provide recommendations for evaluation and follow-up of lung …
individuals for screening and provide recommendations for evaluation and follow-up of lung …
[HTML][HTML] PARP inhibitors in small-cell lung cancer: rational combinations to improve responses
EH Knelson, SA Patel, JM Sands - Cancers, 2021 - mdpi.com
Simple Summary Small-cell lung cancer carries a dismal prognosis with few long-term
treatment options. The enzyme poly-(ADP)-ribose polymerase (PARP), which functions to …
treatment options. The enzyme poly-(ADP)-ribose polymerase (PARP), which functions to …
An overview of lurbinectedin as a new second-line treatment option for small cell lung cancer
S Patel, WJ Petty, JM Sands - Therapeutic Advances in …, 2021 - journals.sagepub.com
Small cell lung cancer (SCLC) is a highly proliferative, aggressive form of lung cancer that
carries a poor prognosis. Recent approvals with new therapeutic options represent the first …
carries a poor prognosis. Recent approvals with new therapeutic options represent the first …
Rates of guideline-concordant surgery and adjuvant chemotherapy among patients with early-stage lung cancer in the US ALCHEMIST study (Alliance A151216)
KL Kehl, D Zahrieh, P Yang, SL Hillman, AD Tan… - JAMA …, 2022 - jamanetwork.com
Importance Standard treatment for resectable non–small cell lung cancer (NSCLC) includes
anatomic resection with adequate lymph node dissection and adjuvant chemotherapy for …
anatomic resection with adequate lymph node dissection and adjuvant chemotherapy for …